Research Article: Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
Introduction:
Chemotherapy remains the cornerstone of first-line therapy in the metastatic setting for the triple-negative breast cancer (TNBC) subtype, as well as for endocrine-therapy resistant luminal breast cancers. The need to improve MBC patients’ outcomes has led to novel therapeutic approaches, including immune checkpoint inhibitors (ICPi) that have changed the treatment landscape for other solid tumors. If MBC is not historically considered as an immunogenic tumor, clinical studies have highlighted the prognostic value…
Read more